Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.40    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.40 (1.067%)
Market Cap: £319.85m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
6th Sep 20246:13 pmRNSHolding(s) in Company
28th Aug 20247:01 amRNSHalf-year Report
28th Aug 20247:00 amRNSResults of AGM on 13 June 2024 – Update Statement
22nd Aug 20247:00 amRNSPRTC Adds Industry Leader to Board of Directors
21st Aug 20247:00 amRNSNotice of Results
1st Jul 20245:00 pmRNSHolding(s) in Company
27th Jun 20245:01 pmRNSPDMR Notification RSU Vesting
27th Jun 20245:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:00 pmRNSCompletion of Tender Offer & Total Voting Rights
24th Jun 20247:00 amRNSResult of Tender Offer
20th Jun 20247:00 amRNSDirector Declaration
13th Jun 20245:42 pmRNSResult of AGM
7th Jun 20245:30 pmRNSHolding(s) in Company
6th Jun 20245:34 pmRNSResult of Meeting
4th Jun 20247:00 amRNSAdditional Disclosure Re: Tender Offer
3rd Jun 20247:00 amRNSTotal Voting Rights
29th May 20241:04 pmRNSPRTC's Akili Enters Into Merger Agreement
23rd May 202412:00 pmRNSPRTC to Present at Jefferies Healthcare Conference
21st May 202412:05 pmRNSPRTC's Vedanta Begins Phase 3 of VE303 in C. diff
20th May 20247:00 amRNSTender Offer
9th May 202412:05 pmRNSPRTC's Seaport Presents Ph1 and Ph2a SPT-300 Data
7th May 202412:05 pmRNSPRTC's Seaport Announces Board/Team Appointments
1st May 20247:00 amRNSTotal Voting Rights
25th Apr 20247:00 amRNSFinal Results
18th Apr 20247:00 amRNSNotice of Results
16th Apr 202412:00 pmRNSPRTC LYT-100 Ph2b in IPF Enrolled; Results Q4 2024
11th Apr 202412:00 pmRNSFDA Grants PRTC's LYT-200 Fast Track Designation
9th Apr 20247:00 amRNSPRTC Launches Seaport w/ $100M; Leadership Changes
19th Mar 20247:00 amRNS$100M Tender Offer
18th Mar 20241:32 pmRNS$14B Acquisition of PRTC’s Karuna by BMS Completed
13th Mar 202411:00 amRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
6th Mar 20247:00 amRNSPDMR Notification RSU Vesting
27th Feb 202412:00 pmRNSPRTC to Present at Cowen and Leerink Conferences
27th Feb 20247:00 amRNSPRTC: Akili Positive Ph3 & Japan PMDA Submission
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20245:30 pmRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 20247:00 amRNSTransaction in Own Shares
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20247:00 amRNSTransaction in Own Shares
18th Jan 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.